Artwork
iconShare
 
Manage episode 521027503 series 9910
Content provided by Journals Online Team and American Society of Clinical Oncology (ASCO). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Journals Online Team and American Society of Clinical Oncology (ASCO) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode of JCO Article Insights, host Dr. Ece Cali Daylan interviews author Dr. Jeffrey Bradley about the article, "Simultaneous Durvalumab and Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer" by Bradley, et al published October 13, 2025.

TRANSCRIPT TO COME

DISCLOSURES

Dr. Bradley Honoria: Mevion Medical Systems, Inc. Consulting or Advisory Role: Varian, Inc, Genentech, Inc. Research Funding: Varian Medical Systems

Dr. Cali Research Funding Company: BeiGene, Nuvalent, Inc., Astra Zeneca

  continue reading

444 episodes